Coya Therapeutics (NASDAQ:COYA) & Xenon Pharmaceuticals (NASDAQ:XENE) Critical Analysis

Coya Therapeutics (NASDAQ:COYA) and Xenon Pharmaceuticals (NASDAQ:XENE) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, valuation and profitability.

Profitability

This table compares Coya Therapeutics and Xenon Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Coya Therapeutics	-270.22%	-52.05%	-46.34%
Xenon Pharmaceuticals	N/A	-43.98%	-41.72%

Volatility and Risk

Coya Therapeutics has a beta of 0.61, suggesting that its share price is 39% less volatile than the S&P 500. Comparatively, Xenon Pharmaceuticals has a beta of 0.61, suggesting that its share price is 39% less volatile than the S&P 500.

Institutional and Insider Ownership

39.8% of Coya Therapeutics shares are held by institutional investors. Comparatively, 95.5% of Xenon Pharmaceuticals shares are held by institutional investors. 6.1% of Coya Therapeutics shares are held by insiders. Comparatively, 2.9% of Xenon Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Coya Therapeutics and Xenon Pharmaceuticals”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coya Therapeutics	$7.95 million	13.08	-$21.23 million	($1.07)	-4.14
Xenon Pharmaceuticals	$7.50 million	760.79	-$345.91 million	($4.74)	-12.45

Coya Therapeutics has higher revenue and earnings than Xenon Pharmaceuticals. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than Coya Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and target prices for Coya Therapeutics and Xenon Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coya Therapeutics	1	0	6	0	2.71
Xenon Pharmaceuticals	1	0	14	2	3.00

Coya Therapeutics presently has a consensus price target of $15.33, indicating a potential upside of 246.05%. Xenon Pharmaceuticals has a consensus price target of $77.13, indicating a potential upside of 30.68%. Given Coya Therapeutics’ higher probable upside, analysts clearly believe Coya Therapeutics is more favorable than Xenon Pharmaceuticals.

Summary

Xenon Pharmaceuticals beats Coya Therapeutics on 8 of the 14 factors compared between the two stocks.

About Coya Therapeutics

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.